Pharmosa Biopharm Inc. (TPEX: 6875)

Pharmosa Biopharm Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	27.78	8.46	-266.51	-256.48	-181.7
Depreciation & Amortization	26.79	23.32	12.7	11.79	10.62
Other Amortization	-	-	-	0.01	-
Loss (Gain) on Equity Investments	-4.92	-5.5	-3.93	-0.66	-4.63
Stock-Based Compensation	3.58	0.87	0.59	15.04	4
Other Operating Activities	-4.53	-	-0.02	-0.02	-
Change in Accounts Receivable	-1.72	-1.18	0.03	-0.14	-0.15
Change in Inventory	-36.04	-21.91	-	-	-
Change in Accounts Payable	-2.18	0.59	-	2	-0.77
Change in Other Net Operating Assets	19.09	37.79	-1.19	-9.05	-8.83
Operating Cash Flow	56.74	42.42	-258.31	-237.51	-181.45
Capital Expenditures	-150.19	-81.46	-10.16	-3.06	-7.05
Sale (Purchase) of Intangibles	-0.05	-0.01	-0.03	-0.19	-
Other Investing Activities	-9.87	-12.38	0.02	8	1.99
Investing Cash Flow	-160.1	-93.84	-10.17	4.75	-5.07
Short-Term Debt Issued	-	-	-	-	161
Long-Term Debt Issued	-	-	-	-	9.5
Total Debt Issued	-	-	-	-	170.5
Short-Term Debt Repaid	-	-	-	-61	-165
Long-Term Debt Repaid	-	-14.22	-15.9	-26.34	-33.99
Total Debt Repaid	-21.21	-14.22	-15.9	-87.34	-198.99
Net Debt Issued (Repaid)	-21.21	-14.22	-15.9	-87.34	-28.48
Issuance of Common Stock	1,324	367.18	495.42	367.02	637.29
Other Financing Activities	-	-	-	-	-12
Financing Cash Flow	1,303	352.97	479.52	279.68	596.81
Foreign Exchange Rate Adjustments	0.01	0	0.01	-	-
Net Cash Flow	1,200	301.55	211.05	46.93	410.29
Free Cash Flow	-93.45	-39.04	-268.47	-240.57	-188.5
Free Cash Flow Margin	-28.83%	-12.41%	-	-	-
Free Cash Flow Per Share	-0.78	-0.34	-2.72	-2.83	-3.96
Cash Interest Paid	3.48	2.86	0.65	1.21	3.86
Levered Free Cash Flow	-93.12	-50.37	-165.23	-135.95	-
Unlevered Free Cash Flow	-90.94	-48.59	-164.83	-135.19	-
Change in Net Working Capital	-35.08	-10.46	-1.78	-3.17	-

Source: S&P Capital IQ. Standard template. Financial Sources.